As the medical publishing industry evolves, and journals expand into non-print new media, it's a good time to explore the function of medical journals in the professional lives of PAs and NPs. Will the experience of receiving a journal in the mail soon be a thing of the past? What do we get out of print media that we don't get online, and vice versa? And, in addition to clinical practice information, what can the engaged reader get out of the publications they read? PA Gary Falcetano, publisher of Clinician Reviews and Emergency Medicine, joins host Lisa Dandrea Lenell to discuss the relevance of PA/NP journals, their evolution in the 21st century, and a model for an engaged journal reader.
On Paper: The Evolution of Medical Media
Share this program on:
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Details
Presenters
Recommended
Details
Presenters
Overview
As the medical publishing industry evolves, and journals expand into non-print new media, it's a good time to explore the function of medical journals in the professional lives of PAs and NPs. Will the experience of receiving a journal in the mail soon be a thing of the past? What do we get out of print media that we don't get online, and vice versa? And, in addition to clinical practice information, what can the engaged reader get out of the publications they read? PA Gary Falcetano, publisher of Clinician Reviews and Emergency Medicine, joins host Lisa Dandrea Lenell to discuss the relevance of PA/NP journals, their evolution in the 21st century, and a model for an engaged journal reader.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Cardiology
Phase 3 study results of plozasiran in patients with FCS
<p>Phase 3 study results of plozasiran in patients with FCS</p>
CME/CE
Evolutions in Duchenne Muscular Dystrophy: Treatment Implications for the Present and Future
1.00 credits
<p>Evolutions in Duchenne Muscular Dystrophy: Treatment Implications for the Present and Future</p>
CME/CE
Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair’s Perspective
0.25 credits
<p>Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair’s Perspective</p>
MinuteCE®
HF Management for Patients with Comorbid Conditions
0.75 credits
<p>HF Management for Patients with Comorbid Conditions</p>
MinuteCE®
Level Up Your Skills: Tailoring Management of HF
0.75 credits
<p>Level Up Your Skills: Tailoring Management of HF</p>
NeuroFrontiers
Rozanolixizumab for Myasthenia Gravis: An Alternative to Corticosteroids
<p>Rozanolixizumab for Myasthenia Gravis: An Alternative to Corticosteroids</p>
Cardiology
Kidney Risk Stratification in Finerenone Treatment: FINEARTS-HF Trial
<p>Kidney Risk Stratification in Finerenone Treatment: FINEARTS-HF Trial</p>
ACC Action Center
Semaglutide improves walking distance, symptoms and QoL in patients with PAD and T2D
<p>Semaglutide improves walking distance, symptoms and QoL in patients with PAD and T2D</p>
Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?